The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab
Küçük Resim Yok
Tarih
2021
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Wiley Online
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
With the onset of the Coronavirus disease 2019 (COVID?19) pandemic, we had concerns about managing the treatments of the patients who received biological therapy. To share our experience, we described the clinical course of a patient with COVID?19 who used ixekizumab. A 46?year?old female patient with hypertension, bronchiectasis, allergic rhinitis, house dust allergy, chronic plaque?type psoriasis, and psoriatic arthritis with a positive QuantiFERON blood test used ixekizumab 160?mg, perindopril/indapamide combination, and received isoniazid for tuberculosis prophylaxis with a dose of 300?mg/day. She continued ixekizumab treatment for 6?months. After the last dose of the ixekizumab, the patient had complaints of mild fever (37.5°C) and coughing for 3?days. She contacted a person who had a positive polymerase chain reaction (PCR) 6?days ago for severe acute respiratory syndrome coronavirus 2 (SARS?CoV?2). The patient's nasopharyngeal swab PCR test was found to be positive for SARS?CoV?2. At admission, the patient's oxygen saturation was 98%, and her lung tomography had a bilateral ground?glass appearance. She was hospitalized in the infectious diseases service, and she began to receive favipiravir (1600?mg orally twice a day on the first day, and followed by 600?mg orally twice a day), enoxaparin sodium solution s.c. 60?mg/0.6 mL/day, and paracetamol 500?mg/day p.o. On the third day of the treatment, her fever decreased, and she had a complaint of mild shortness of breath. Favipiravir treatment was completed and stopped on the fifth day. At the end of the first week, the dyspnea was completely recovered, and the fever did not occur after discharge. After a week, symptoms of sneezing and nasal congestion started. Two SARS?CoV?2 nasopharyngeal swab samples repeated 30?days after the initial diagnosis yielded negative results. One ixekizumab dose was skipped, and the treatment continued 1?month later. The patient had not new psoriatic lesions, and joint complaints during and after the COVID 19 infection. The psoriasis area severity index (PASI) value of the patient, which was 11.8 when she started the ixekizumab treatment, was measured as 1.2 in the sixth week of the treatment. The PASI value did not change during and after the COVID?19 infection. Interleukin?17 (IL?17) was considered to promote viral persistence by inhibiting the apoptosis of virus?infected cells and to cause Th17?related cytokine storm syndrome. 1 In a recent study of the Italian psoriasis?biologics?COVID working group, the researchers thought that biological therapies could reduce the cytokine storm which may lead to multiorgan failure, ARDS, and death. 2 Therefore, inhibition of IL?17 may have contributed to the mild course of the disease in the present case.
Açıklama
Anahtar Kelimeler
Kaynak
Dermatologic Therapy
WoS Q Değeri
Q2
Scopus Q Değeri
Q1
Cilt
34
Sayı
2
Künye
Güder, S. ve Güder, H. (2021). The course of COVID-19 infection and prolonged sneezing and nasal congestion in a patient using ixekizumab. Dermatologic Therapy, Wiley Online. 34(2).
